Yael A. Weintraub

6 Weizmann Street, 6423906
Tel Aviv, TA 64239, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease.

Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease.

Journal: Journal of pediatric gastroenterology and nutrition

Published: November 12, 2025

The circadian clock, metabolism, and inflammation-the holy trinity of inflammatory bowel diseases.

The circadian clock, metabolism, and inflammation-the holy trinity of inflammatory bowel diseases.

Journal: Clinical science (London, England : 1979)

Published: March 30, 2025

Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature.

Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature.

Journal: Archives of dermatological research

Published: February 26, 2025

Anti-Saccharomyces cerevisiae antibodies positivity is not linked to antitumor necrosis factor-α durability in pediatric Crohn's disease patients: A single-center study.

Anti-Saccharomyces cerevisiae antibodies positivity is not linked to antitumor necrosis factor-α durability in pediatric Crohn's disease patients: A single-center study.

Journal: Journal of pediatric gastroenterology and nutrition

Published: February 04, 2025

Safety and Effectiveness of QingDai (Indigo naturalis) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label Trial.

Safety and Effectiveness of QingDai (Indigo naturalis) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label Trial.

Journal: Inflammatory bowel diseases

Published: February 04, 2025

Maintenance-phase serum anti-TNF levels are not associated with mucosal healing in pediatric Crohn's disease.

Maintenance-phase serum anti-TNF levels are not associated with mucosal healing in pediatric Crohn's disease.

Journal: Journal of pediatric gastroenterology and nutrition

Published: November 06, 2024

The circadian clock in inflammatory bowel diseases.

The circadian clock in inflammatory bowel diseases.

Journal: Trends in molecular medicine

Published: October 07, 2024

Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition.

Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition.

Journal: Inflammatory bowel diseases

Published: September 22, 2024

Endomysial antibodies or anti-tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease.

Endomysial antibodies or anti-tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease.

Journal: Journal of pediatric gastroenterology and nutrition

Published: July 20, 2024

The Nancy Histopathological Index has limited value in predicting clinical outcomes in newly diagnosed pediatric patients with ulcerative colitis.

The Nancy Histopathological Index has limited value in predicting clinical outcomes in newly diagnosed pediatric patients with ulcerative colitis.

Journal: Journal of pediatric gastroenterology and nutrition

Published: June 05, 2024

Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN.

Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN.

Journal: Paediatric drugs

Published: April 14, 2024

Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors.

Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors.

Journal: Clinical and experimental dermatology

Published: April 03, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026